Pfizer CEO: Metsera deal gives us ‘one of the most exciting, advanced portfolios’ in obesity drugs

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical development and manufacturing.